Case Report

Immediate Effect of Baricitinib on Arthritis and Biological Disease-Modifying Antirheumatic Drug-Induced Psoriasis-Like Skin Lesions in Two Patients with Rheumatoid Arthritis

Yoshifumi Tada, Nobuyuki Ono, and Syuichi Koarada

Department of Rheumatology, Faculty of Medicine, Saga University, Saga 849-8501, Japan

Correspondence should be addressed to Yoshifumi Tada; taday@cc.saga-u.ac.jp

Received 26 June 2020; Revised 6 January 2021; Accepted 30 January 2021; Published 8 February 2021

Copyright © 2021 Yoshifumi Tada et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Biological disease-modifying antirheumatic drugs (bDMARDs) are very effective for treating rheumatoid arthritis (RA). However, they sometimes induce adverse events such as psoriasis-like skin lesions. We describe psoriasis-like skin lesions that developed simultaneously with an RA flare in patient 1 during treatment with abatacept and in patient 2 soon after starting certolizumab pegol. The skin lesions persisted in patient 2 despite stopping certolizumab. Baricitinib was initiated because of RA flare and resulted in immediate beneficial effects on arthritis as well as skin lesions. The RA went into remission in both patients, and the psoriasis-like skin lesions disappeared within four weeks (patient 1) and three months (patient 2).

1. Introduction

The introduction of bDMARDs has remarkably changed the strategy of treating RA. Although they are very effective, side effects can include infection, allergies, and autoimmune phenomenon. The psoriasis and psoriasis-like skin lesions that sometimes develop while under bDMARD therapy are now referred to as paradoxical psoriasis [1, 2]. The estimated incidence of psoriasis in the RA population treated with antitumor necrosis factor (TNF) drugs ranges from 1.04 to 2.31/1000 person-years [2], and these lesions are an important cause of bDMARD discontinuation. Recent investigations have shown that the mechanisms of paradoxical reactions to anti-TNF agents are associated with hyperactivation of type 1 interferons (IFN) [3]. We present two patients with RA who developed psoriasis-like skin lesion as a response to bDMARDs and in whom baricitinib rapidly alleviated the skin lesions as well as the RA.

2. Case Presentation

2.1. Case 1. A 74-year-old woman who developed RA in 2009 had been treated with conventional DMARD, golimumab, and prednisolone for several years, but these became ineffective, and she was referred to our hospital in 2015. She was positive for anticyclic citrullinated peptide antibody (ACPA) (>500 U/mL) and rheumatoid factor (RF, >30 U/L), and X-rays showed erosions in both wrist joints. Treatment with abatacept 500 mg div every four weeks plus methotrexate (MTX) was effective, and the RA went into remission after six months. Prednisolone was then tapered. Two months after MTX withdrawal, in 2018, due to mild liver damage (alanine transferase 114 U/L), the RA flared, and pqrosis-like skin lesions developed in the upper and lower extremities (Figure 1(a)). The patient had no history or family history of psoriasis and never smoked. A skin biopsy showed elongated rete ridges, parakeratosis, and mononuclear cell infiltration around vessels in the dermis (Figure 1(b)) resembling psoriasis. Topical steroids were prescribed by a dermatologist, but the effect was limited. Because her RA had simultaneously become active with the simplified disease activity index (SDAI) of 18.3, we stopped abatacept and started on baricitinib 4 mg/day, which resulted in the SDAI decreasing to 3.54 and the disappearance of the psoriasis-like skin lesions within four weeks. RF also decreased from 423 U/L to 232 U/L in three months.
One year later, the RA remained in remission (SDAI: 2.02), and she was free of skin lesions.

2.2. Case 2. A 65-year-old woman, who developed RA with positive ACPA (>100 U/mL) and RF (27 U/L), was also diagnosed with Sjögren syndrome (anti-SS-A antibody > 500 U/mL). She had been treated with abatacept and golimumab together with MTX, but both bDMARDs were terminated due to the emergence of side effects consisting of liver damage and skin eruptions. Liver biopsy denied autoimmune hepatitis, and liver damage improved with discontinuation of bDMARDs. Two months after starting certolizumab pegol in 2014 (initially, 400 mg s.c. every two weeks for one month followed by 200 mg s.c. every two weeks with MTX at 8 mg/week), skin eruptions appeared on her back and right elbow (Figure 2(a)). A skin biopsy showed marked elongated rete ridges, mild parakeratosis, and pronounced lymphoid cell infiltration in the upper dermis, suggesting psoriasis-like lesions (Figure 2(b)). She had no history or family history of psoriasis and never smoked. After withdrawing certolizumab pegol and topical steroids, the skin lesion in her back gradually disappeared, whereas that in the right elbow persisted. In 2018, we initiated baricitinib (2 mg/day) in addition to MTX (8 mg/week) because of continuous arthritis in her wrist and ankles. This combination exerted a remarkable effect on the RA activity and the skin lesion. SDAI decreased from 8.62 to 3.65 (four weeks) and 1.96 (three months), and the psoriasis-like lesion in the right elbow also disappeared within three months. One year later, the RA remained in remission (SDAI: 1.11), and she was free of skin lesions.

3. Discussion

We described two women with RA who developed psoriasis-like skin lesions in response to bDMARD treatment. Baricitinib rapidly resolved the lesions and alleviated the RA in both of them. The pathological and macroscopic findings of the skin lesions were similar between the patients, but the bDMARD and time to onset differed. The lesions appeared after three years of abatacept therapy and, at the same time, as an RA flare in one patient and two months after starting certolizumab pegol in the other. The skin lesions in patient 2 had persisted for almost four years but disappeared under baricitinib within three months. To our knowledge, this effect of baricitinib has not been previously reported.

Anti-TNF agents sometimes induce psoriasis or psoriasis-like skin lesions referred to as paradoxical psoriasis [2], the pathogenesis of which has recently been associated with an increase in type I IFN activity. Increased expression of MxA, a surrogate marker for type I IFN, was initially identified in paradoxical psoriasis induced by TNF inhibitors, suggesting increased production of type I IFN [1]. Recent investigations have found that the immunological phenotypes differ between paradoxical and classical psoriasis; that is, type I IFN activity and plasmacytoid dendritic cell (pDC) infiltration are significantly increased, whereas CD8-T cell infiltration of the dermis is lower in paradoxical psoriasis [3]. A study of a mouse model of skin injury showed that hyperacanthosis, pDC infiltration, and type I IFN expression were enhanced by treatment with an anti-TNF antibody, indicating that a blockade of TNF activity promotes type I IFN overexpression that leads to skin lesions [3]. In support of this theory, it has been shown that TNF-α inhibited the generation of pDC from hematopoietic progenitors, and IFN-α production from pDC exposed to influenza virus [4]. In addition to paradoxical psoriasis, the adverse immunological effects of anti-TNF agents, antidrug antibody (ADA), and antinuclear antibody (ANA) production are also associated with increased levels of type I IFN, and these can induce secondary unresponsiveness to anti-TNF agents and drug-induced lupus [5, 6]. These findings suggest that anti-TNF therapy sometimes induces an increase in type I IFN activity that can promote paradoxical psoriasis, ADA that leads to a poor response to bDMARDs, and ANA and other autoantibodies that can cause drug-induced lupus.

In addition to anti-TNF drugs, a randomized, placebo-controlled trial showed that abatacept was effective against psoriatic arthritis and psoriatic skin lesions [7], whereas others showed that abatacept induces psoriatic skin lesion as
an adverse event [8, 9]. This can be interpreted as another type of paradoxical psoriasis. The psoriasis-like skin lesions and the concomitant RA flare were rapidly alleviated by administering baricitinib in patient 2, suggesting that a common mechanism is involved. The mechanisms remain unknown, but whether type I IFN activity is enhanced in these patients should be investigated.

The treatment of paradoxical psoriasis is challenging. The choice to continue, suspend, or switch the bDMARD has to be carefully made by weighing the severity of the skin lesions against the control of RA. Although bDMARDs can be discontinued in patients with well-controlled RA, active RA should be treated by continuing the same drug or by switching to other types of bDMARDs with different modes of action [10]. In fact, switching to tocilizumab has resulted in good outcomes for both arthritis and anti-TNF-induced skin reactions [11, 12]. Baricitinib is a targeted synthetic antirheumatic drug that mainly inhibits the activities of Janus kinases (Jak) 1 and 2. It inhibits IFN-α-induced B-cell differentiation to plasmablasts and IL-6 production by inhibiting Jak signaling [13]. In addition to RA, baricitinib has improved manifestations and IFN biomarkers in patients with various IFN-mediated autoimmune diseases, referred to as interferonopathies [14]. It has also proven effective against systemic lupus erythematosus, in which type I IFN are considered to be major players in its pathogenesis [15]. These findings indicate that baricitinib can inhibit enhanced pathological type I IFN activities under various conditions. Considering this background, we treated our patients with baricitinib, which resulted in an immediate response against RA and psoriatic skin lesions.

4. Conclusion

Psoriasis-like lesions develop in 2–5% of patients with RA treated by bDMARDs, and its management is a matter of concern, especially when skin lesions persist and/or RA remains active. Because recent investigations have shown that increased type I IFN activity is a significant factor in the development of psoriasis-like skin lesions, Jak inhibitors that block type I IFN signaling might be good candidates for treating this condition. However, more case reports are needed to validate our findings. Furthermore, immunological analyses should provide insight into the mechanisms of baricitinib treatment for paradoxical psoriasis.

Conflicts of Interest

Y. T., N. O., and S. K. have received speaker fees from Bristol Myers Squibb, Astellas, UCB Japan, and Eli Lilly.

Acknowledgments

The authors thank Dr. Yoko Oda for providing the biopsy specimen of patient 1 and Dr. Takuya Inoue for preparing histological images.

References

[1] G. C. de Gannes, M. Ghoreishi, J. Pope et al., “Psoriasis and pustular dermatitis triggered by TNF-a inhibitors in patients with rheumatologic conditions,” Archives of Dermatological Research, vol. 143, pp. 223–231, 2007.
[2] E. Toussirot and F. Aubin, “Paradoxical reactions under TNF-1 blocking agents and other biological agents given for chronic immune-mediated diseases: an analytical and comprehensive overview,” RMD Open, vol. 2, Article ID e000239, 2016.
[3] C. Conrad, J. D. Domizio, A. Mylonas et al., “TNF blockade induces a dysregulated type I interferon response without autoimmunity in paradoxical psoriasis,” Nature Communications, vol. 9, pp. 25–35, 2018.
[4] A. K. Palucka, J.-P. Blanck, L. Bennett, V. Pascual, and J. Buchereau, “Cross-regulation of TNF and IFN- in autoimmune diseases,” Proceedings of the National Academy of Sciences, vol. 102, no. 9, pp. 3372–3377, 2005.
[5] Y. Ishikawa, T. Fujii, Kondo et al., “Immunogenicity and lupus-like autoantibody production can be linked to each other along with type I interferon production in patients with rheumatoid arthritis treated with infliximab: a retrospective study of a single center cohort,” PLoS One, vol. 11, Article ID e0162896, 2016.
[6] Y. Ishikawa, M. Hashimoto, H. Ito et al., “Anti-nuclear antibody development is associated with poor treatment
response to biological disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis,” *Seminars in Arthritis and Rheumatism*, vol. 49, no. 2, pp. 204–210, 2019.

[7] P. Tanaka, M. C. Genovese, G. Gladstein et al., “Abatacept in the treatment of patients with psoriatic arthritis: results of a six-month, multicenter, randomized, double-blind, placebo-controlled, phase II trial,” *Arthritis & Rheumatism*, vol. 63, no. 4, pp. 939–948, 2011.

[8] I. Kivitz, C. Nguyen Thi Hong, Y. Ueki, N. Kambe, and H. Okamoto, “Psoriatic skin lesions induced by abatacept: case report and review of the published work,” *The Journal of Dermatology*, vol. 44, no. 7, pp. 845-846, 2017.

[9] G. Ozen, S. Pedro, R. Schumacher, T. A. Simon, and K. Michaud, “Safety of abatacept compared with other biologic and conventional synthetic disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis: data from an observational study,” *Arthritis Res Ther*, vol. 21, p.141, 2019.

[10] S. J. Li, L. M. Perez-Chada, and J. F. Merola, “TNF inhibitor-induced psoriasis: proposed algorithm for treatment and management,” *Journal of Psoriasis and Psoriatic Arthritis*, vol. 4, no. 2, pp. 70–80, 2019.

[11] J. Rueda-Gotor, M. A. González-Gay, R. Blanco Alonso, C. Gonzalez-Vela, C. Lopez-Obregon, and M. A. González-López, “Successful effect of tocilizumab in anti-TNF-α-induced palmoplantar pustulosis in rheumatoid arthritis,” *Joint Bone Spine*, vol. 79, no. 5, pp. 510–513, 2012.

[12] M. Shimizu, Y. Hamaguchi, S. Ishikawa, K. Ueno, and A. Yachie, “Successful treatment with tocilizumab of a psoriasiform skin lesion induced by etanercept in a patient with juvenile idiopathic arthritis,” *Modern Rheumatology*, vol. 25, no. 6, pp. 972-973, 2015.

[13] S. Kubo, S. Nakayamada, K. Sakata et al., “Janus kinase inhibitor baricitinib modulates human innate and adaptive immune system,” *Frontiers in Immunology*, vol. 9, p. 1510, 2018.

[14] G. A. M. Sanchez, A. Reinhart, S. Ramsey et al., “JAK1/2 inhibition with baricitinib in the treatment of auto-inflammatory interferonopathies,” *Journal of Clinical Investigation*, vol. 128, no. 7, pp. 3041-3052, 2018.

[15] D. J. Wittkowski, R. A. Furie, Y. Tanaka et al., “Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial,” *The Lancet*, vol. 392, no. 10143, pp. 222–231, 2018.